To The Moon

$Hims & Hers Health Inc.(HIMS)$  indeed 

$Hims & Hers Health Inc.(HIMS)$  The pre-market surge in Hims & Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme

$Hims & Hers Health Inc.(HIMS)$  40% jump overnight ...

Congrats to all the $Hims & Hers Health Inc.(HIMS)$   holders — the stock just jumped 40% after hours! 🚀 Looks like Novo Nordisk (Novo Nordisk (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded GLP-1 receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: "We are in ongoing dialogue with companies that can help improve patient access to regulatory

$Hims & Hers Health Inc.(HIMS)$  7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser]  [Miser]  [Miser]  

Divorced Last Year, Married Again This Monday? Novo & Hims’ Comeback” $Hims & Hers Health Inc.(HIMS)$   Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours.  The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance  and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨

Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!  $Hims & Hers Health Inc.(HIMS)$    Here's why this could be a game-changer for Hims & Hers (and patients worldwide):   Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generi

Pure $Hims & Hers Health Inc.(HIMS)$ delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not "sandbagged", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of "macro and War in Iran" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w

$HIMS 20260327 15.0 PUT$  

Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant $Novo-Nordisk A/S(NVO)$ is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca

Peptides could be a new multi-billion-dollar market for companies like Hims & Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and

$Hims & Hers Health Inc.(HIMS)$  indeed 

$Hims & Hers Health Inc.(HIMS)$  The pre-market surge in Hims & Hers Health Inc. following a reported settlement with Novo Nordisk is a significant narrative shift. For months, regulatory uncertainty around weight-loss drug distribution had weighed on sentiment. If Novo’s Wegovy is indeed sold through the Hims platform, it transforms HIMS from a telehealth subscription company into a distribution gateway for GLP-1 therapies, which is a far larger market. Can it reclaim $70? A move toward the prior high is plausible, but the 49% gap introduces short-term risks. Bullish factors Direct access to FDA-approved GLP-1 drugs boosts credibility and revenue potential. Telehealth + obesity treatment is one of the fastest-growing healthcare segme

$Hims & Hers Health Inc.(HIMS)$  40% jump overnight ...

Congrats to all the $Hims & Hers Health Inc.(HIMS)$   holders — the stock just jumped 40% after hours! 🚀 Looks like Novo Nordisk (Novo Nordisk (NVO)) may have dropped the lawsuit and decided to partner with HIMS, selling Novo-branded GLP-1 receptor agonists. $NVO Novo Nordisk on Danish newspaper Børsen: "We are in ongoing dialogue with companies that can help improve patient access to regulatory

Divorced Last Year, Married Again This Monday? Novo & Hims’ Comeback” $Hims & Hers Health Inc.(HIMS)$   Novo and Hims look like they’re getting married again 💍 after last year’s messy divorce. Hims pops 35% in after hours.  The two companies are expected to announce a new partnership as early as Monday, according to a person familiar with the matter who spoke on condition of anonymity. They were previously together, but Novo abruptly called it quits after Hims refused to stop promoting and selling copycat medications. Now it seems the former couple may be giving love another chance  and Muthu boy is very happy to see the reunion 😊. I wonder… will they order my roti prata from my prata shop? 🥞✨

Big news for weight loss access! Semaglutide patents are expiring soon in countries like India, China, and Brazil (starting March 2026) – meaning super-cheap generic versions are coming!  $Hims & Hers Health Inc.(HIMS)$    Here's why this could be a game-changer for Hims & Hers (and patients worldwide):   Lower Costs As patents expire, raw ingredient (API) prices will crash. If manufacturing drops to ~$3/month, Hims & Hers can slash subscription prices big time – making effective weight loss meds affordable instead of $200–$1,000/month for branded versions. More people can finally access it! Global Expansion Hims & Hers is already pushing internationally (just entered Canada!). With cheap, legal generi

Facing Eli Lilly’s competition and short-term sales slumps, can NVO reclaim its GLP-1 dominance in the $150B market? Are you bullish on its long-term bet, or is LLY a better pick? Share your thoughts on the weight-loss drug race below! To consolidate its position in the global weight-loss drug market, Danish pharmaceutical giant $Novo-Nordisk A/S(NVO)$ is accelerating capacity expansion. According to local media reports on Monday, the company will invest €432 million (approximately $507 million) to upgrade its factory in Athlone, Ireland, to produce its blockbuster weight-loss drug Wegovy for markets outside the United States. A company spokesperson has confirmed the scale of this investment. The upgrade will significantly enhance its production ca

$Hims & Hers Health Inc.(HIMS)$  7 Mar - Missed this 40%+ pump. Waited for $13 but did not happened. Congrats to those who got it at $14-$15 when no one believed in the stock.. [Miser]  [Miser]  [Miser]  

Pure $Hims & Hers Health Inc.(HIMS)$ delulu copium. Bearish catalysts: 1) Still trading at 32 P/E, despite the core profit driver under attack. If GLP1s go to zero, profits fall 80-120%. Overvalued. 2) Growth is not "sandbagged", its the opposite. $HIMS 2026 and 2030 guidances are aggressive and unachievable without M&A. 3) Newly acquired international segments are stinkers and unprofitable. Everyone knows that $HIMS is the sucker to sell to. Watch for international growth to suffer because of "macro and War in Iran" (Excuses). 4) Peptide approval is not the catalyst HIMS hopes for. It's the opposite, regulators are talking of banning the sale of certain peptides and stricter regulations. 5) Wearables is just delusion, HIMS can't compete w

$HIMS 20260327 15.0 PUT$  

Peptides could be a new multi-billion-dollar market for companies like Hims & Hers $HIMS. What are these peptides, and what do they do? Here's what you need to know about all 19 peptides in question today, 14 of which may soon be legal to compound (according to RFK) 👇 1. BPC-157 Note: These infographics are made by Gemini and are for informational purposes only. 2. Thymosin Alpha-1 (Ta1) 3. Thymosin Beta-4 Fragment (TB-500) 4. AOD-9604 5. CJC-1295 6. Ipamorelin Acetate 7. Selank Acetate (TP-7) 8. Semax 9. GHK-Cu (Copper Peptide) 10. GHRP-2 11. GHRP-6 12. Epitalon 13. KPV 14. Kisspeptin-10 15. Melanotan II 16. MOTS-c 17. PEG-MGF (Pegylated Mechano Growth Factor) 18. Emideltide (DSIP - Delta Sleep-Inducing Peptide) 19. Cathelicidin LL-37 For SG users only, Welcome to open a CBA today and